TY - JOUR
T1 - Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient
AU - Amariglio, Ninette
AU - Hirshberg, Abraham
AU - Scheithauer, Bernd W.
AU - Cohen, Yoram
AU - Loewenthal, Ron
AU - Trakhtenbrot, Luba
AU - Paz, Nurit
AU - Koren-Michowitz, Maya
AU - Waldman, Dalia
AU - Leider-Trejo, Leonor
AU - Toren, Amos
AU - Constantini, Shlomi
AU - Rechavi, Gideon
N1 - Funding Information:
We thank the Kahn Family Fund for Humanitarian Support for their generous support of our research. We thank R. Kalt, E. Moscovich, B. Brilovich, K. Siegalov, and G. Ishoiev for excellent technical assistance. GR holds the Djerassi Chair in Oncology, Tel Aviv University. We acknowledge the Russian physicians and YL for providing details of the treatment in Moscow.
PY - 2009/2/1
Y1 - 2009/2/1
N2 - Background Neural stem cells are currently being investigated as potential therapies for neurodegenerative diseases, stroke, and trauma. However, concerns have been raised over the safety of this experimental therapeutic approach, including, for example, whether there is the potential for tumors to develop from transplanted stem cells. Methods and Findings A boy with ataxia telangiectasia (AT) was treated with intracerebellar and intrathecal injection of human fetal neural stem cells. Four years after the first treatment he was diagnosed with a multifocal brain tumor. The biopsied tumor was diagnosed as a glioneuronal neoplasm. We compared the tumor cells and the patient's peripheral blood cells by fluorescent in situ hybridization using X and Y chromosome probes, by PCR for the amelogenin gene X-and Y-specific alleles, by MassArray for the ATM patient specific mutation and for several SNPs, by PCR for polymorphic microsatellites, and by human leukocyte antigen (HLA) typing. Molecular and cytogenetic studies showed that the tumor was of nonhost origin suggesting it was derived from the transplanted neural stem cells. Microsatellite and HLA analysis demonstrated that the tumor is derived from at least two donors. Conclusions This is the first report of a human brain tumor complicating neural stem cell therapy. The findings here suggest that neuronal stem/progenitor cells may be involved in gliomagenesis and provide the first example of a donor-derived brain tumor. Further work is urgently needed to assess the safety of these therapies.
AB - Background Neural stem cells are currently being investigated as potential therapies for neurodegenerative diseases, stroke, and trauma. However, concerns have been raised over the safety of this experimental therapeutic approach, including, for example, whether there is the potential for tumors to develop from transplanted stem cells. Methods and Findings A boy with ataxia telangiectasia (AT) was treated with intracerebellar and intrathecal injection of human fetal neural stem cells. Four years after the first treatment he was diagnosed with a multifocal brain tumor. The biopsied tumor was diagnosed as a glioneuronal neoplasm. We compared the tumor cells and the patient's peripheral blood cells by fluorescent in situ hybridization using X and Y chromosome probes, by PCR for the amelogenin gene X-and Y-specific alleles, by MassArray for the ATM patient specific mutation and for several SNPs, by PCR for polymorphic microsatellites, and by human leukocyte antigen (HLA) typing. Molecular and cytogenetic studies showed that the tumor was of nonhost origin suggesting it was derived from the transplanted neural stem cells. Microsatellite and HLA analysis demonstrated that the tumor is derived from at least two donors. Conclusions This is the first report of a human brain tumor complicating neural stem cell therapy. The findings here suggest that neuronal stem/progenitor cells may be involved in gliomagenesis and provide the first example of a donor-derived brain tumor. Further work is urgently needed to assess the safety of these therapies.
UR - http://www.scopus.com/inward/record.url?scp=61449171881&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1000029
DO - 10.1371/journal.pmed.1000029
M3 - Article
C2 - 19226183
AN - SCOPUS:61449171881
SN - 1549-1277
VL - 6
SP - 221
EP - 231
JO - PLoS Medicine
JF - PLoS Medicine
IS - 2
M1 - e1000029
ER -